Safety and cost-effectiveness of individualised screening for diabetic retinopathy: the ISDR open-label, equivalence RCT by Broadbent, Deborah M. et al.
Article
Safety and cost-effectiveness of individualised 
screening for diabetic retinopathy: the ISDR 
open-label, equivalence RCT
Broadbent, Deborah M., Wang, Amu, Cheyne, Christopher P., 
James, Marilyn, Lathe, James, Stratton, Irene M., Roberts, John, 
Moitt, Tracy, Vora, Jiten P., Gabbay, Mark, García-Fiñana, Marta, 
Harding, Simon P. and Thetford, Clare
Available at http://clok.uclan.ac.uk/35881/
Broadbent, Deborah M., Wang, Amu, Cheyne, Christopher P., James, Marilyn, Lathe, 
James, Stratton, Irene M., Roberts, John, Moitt, Tracy, Vora, Jiten P. et al (2021) Safety 
and cost-effectiveness of individualised screening for diabetic retinopathy: the ISDR 
open-label, equivalence RCT. Diabetologia, 64 (1). pp. 56-69. ISSN 0012-186X  
It is advisable to refer to the publisher’s version if you intend to cite from the work.
http://dx.doi.org/10.1007/s00125-020-05313-2
For more information about UCLan’s research in this area go to 
http://www.uclan.ac.uk/researchgroups/ and search for <name of research Group>.
For information about Research generally at UCLan please go to 
http://www.uclan.ac.uk/research/ 
All outputs in CLoK are protected by Intellectual Property Rights law, including
Copyright law.  Copyright, IPR and Moral Rights for the works on this site are retained 
by the individual authors and/or other copyright owners. Terms and conditions for use 
of this material are defined in the http://clok.uclan.ac.uk/policies/
CLoK
Central Lancashire online Knowledge
www.clok.uclan.ac.uk
ARTICLE
Safety and cost-effectiveness of individualised screening for diabetic
retinopathy: the ISDR open-label, equivalence RCT
Deborah M. Broadbent1,2 & Amu Wang1,2 & Christopher P. Cheyne3,4 & Marilyn James5 & James Lathe5 &
Irene M. Stratton6 & John Roberts7 & Tracy Moitt4 & Jiten P. Vora8 & Mark Gabbay9,10 &
Marta García-Fiñana3,4 & Simon P. Harding1,2 & the ISDR Study Group
Received: 14 May 2020 /Accepted: 8 September 2020
# The Author(s) 2020
Abstract
Aims/hypothesis Using variable diabetic retinopathy screening intervals, informed by personal risk levels, offers improved
engagement of people with diabetes and reallocation of resources to high-risk groups, while addressing the increasing prevalence
of diabetes. However, safety data on extending screening intervals are minimal. The aim of this study was to evaluate the safety
and cost-effectiveness of individualised, variable-interval, risk-based population screening compared with usual care, with wide-
ranging input from individuals with diabetes.
Methods This was a two-arm, parallel-assignment, equivalence RCT (minimum 2 year follow-up) in individuals with diabetes aged
12 years or older registered with a single English screening programme. Participants were randomly allocated 1:1 at baseline to
individualised screening at 6, 12 or 24 months for those at high, medium and low risk, respectively, as determined at each screening
episode by a risk-calculation engine using local demographic, screening and clinical data, or to annual screening (control group).
Screening staff and investigatorswere observer-masked to allocation and interval.Datawere collectedwithin the screeningprogramme.
The primary outcomewas attendance (safety). A secondary safety outcomewas the development of sight-threatening diabetic retinop-
athy. Cost-effectiveness was evaluated within a 2 year time horizon from National Health Service and societal perspectives.
Results A total of 4534 participants were randomised. After withdrawals, there were 2097 participants in the individualised screening
arm and 2224 in the control arm. Attendance rates at first follow-up were equivalent between the two arms (individualised screening
83.6%; control arm 84.7%; difference −1.0 [95%CI −3.2, 1.2]), while sight-threatening diabetic retinopathy detection rates were non-
inferior in the individualised screening arm (individualised screening 1.4%, control arm 1.7%; difference −0.3 [95% CI −1.1, 0.5]).
Sensitivity analyses confirmed these findings. No important adverse events were observed.Mean differences in complete case quality-
adjusted life-years (EuroQol Five-Dimension Questionnaire, Health Utilities Index Mark 3) did not significantly differ from zero;
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multiple imputation supported the dominance of individualised screening. Incremental cost savings per person with
individualised screening were £17.34 (95% CI 17.02, 17.67) from the National Health Service perspective and
£23.11 (95% CI 22.73, 23.53) from the societal perspective, representing a 21% reduction in overall programme
costs. Overall, 43.2% fewer screening appointments were required in the individualised arm.
Conclusions/interpretation Stakeholders involved in diabetes care can be reassured by this study, which is the largest ophthalmic
RCT in diabetic retinopathy screening to date, that extended and individualised, variable-interval, risk-based screening is feasible
and can be safely and cost-effectively introduced in established systematic programmes. Because of the 2 year time horizon of the
trial and the long time frame of the disease, robust monitoring of attendance and retinopathy rates should be included in any future
implementation.
Trial registration ISRCTN 87561257
Funding The study was funded by the UK National Institute for Health Research.
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Introduction
Early detection of sight-threatening diabetic retinopathy
(STDR) at a stage allowing timely intervention, through
systematic programmes of screening, is universally
recognised to be important in preventing visual impairment
[1] and reducing its associated costs, but approaches vary
greatly worldwide. The frequency of screening has to date
been annual, based on consensus, and this remains the recom-
mendation inmajor guidelines [2, 3]. However, the prevalence
of diabetes is increasing rapidly [4], increasing the require-
ment for screening, and resources are stretched.
Extending the interval between screening episodes offers
potential cost savings. Some developed countries have
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recommended or implemented 2 yearly and sometimes longer
intervals for people at low risk of progression. Much evidence
supporting extended intervals comes from observational stud-
ies from areas with low incidence rates of STDR [5–8] and
from modelling studies [9]. Safety concerns have been
highlighted by a recent systematic review that called for
RCTs and cost-effectiveness evidence [10], and recent failures
in cancer screening [11]. In addition, the feasibility of
connecting large and disparate datasets is considered challeng-
ing [12].
Based on our previous incidence data [5] we designed an
RCT (the Individualised Screening for Diabetic Retinopathy
[ISDR] study) to investigate the safety, efficacy and cost-
effectiveness of extending screening intervals in low-risk indi-
viduals with diabetes, with more frequent intervals for those at
high risk. We used the emerging methodology and technolo-
gies of personalised risk prediction [13, 14] and data linkage
to develop an individualised, variable-interval, risk-based
screening approach. Individualised clinical care offers oppor-
tunities for improved patient engagement. We also wanted to
test the feasibility and stability of linking routine data across
varying National Health Service (NHS) domains in an inte-
grated approach. We tested the hypothesis of equivalence
between attendance rates, as a primary measure of safety, for
individualised and annual screening.
Methods
Study design and participants Individuals with diabetes
attending for diabetic retinopathy screening were invited to
participate in a single-site, two-arm, parallel-assignment,
equivalence RCT conducted in all community screening
clinics in the Liverpool Diabetic Eye Screening Programme,
which is part of the English National Diabetic Eye Screening
Programme. The rationale, design and methodology have
been published elsewhere [15], and the protocol and statistical
and health economics analysis plans are available online [16].
In brief, inclusion criteria comprised: age 12 years or older,
attending for retinal screening during the recruitment period,
registered with a participating general practitioner, with no
retinopathy or retinopathy/maculopathy less than the defini-
tion of screen-positive diabetic retinopathy, gradable digital
retinal images in both eyes and did not opt out of the data
warehouse (see below).
The English National Screening Committee definition of a
screen-positive result was used, comprising any of: (1) moder-
ate preproliferative diabetic retinopathy (R2) (equivalent to
moderate non-proliferative diabetic retinopathy) or worse
(any of: multiple deep blot haemorrhages, venous beading,
intraretinal microvascular abnormalities, or worse); (2) new
proliferative diabetic retinopathy (R3A); (3) maculopathy
(M1) (any of: exudates ≤1 disc diameter (DD) from the foveal
centre, group exudates ≥1/2 disc area (DA) ≥1 DD from the
foveal centre, haemorrhage ≤1 DD from the foveal centre if
visual acuity ≥+0.30 log minimal angle of resolution); (4)
ungradable images; or (5) other significant sight-threatening
disease [17, 18]. The definition of STDR was met when either
retinopathy or maculopathy, as defined above, was confirmed
on clinical examination by a retinal specialist (R2, R3A and/or
M1 in England).
A patient and public involvement (PPI) group was embed-
ded in all aspects of the study design, delivery and interpreta-
tion. The Liverpool Clinical Trials Research Centre developed
electronic case report forms, information systems, quality assur-
ance systems and systems to minimise operational bias (see
electronic supplementary material [ESM] Methods, Clinical
Trials Research Centre procedures). Ethics approval was by
Preston NHS Research Ethics Committee (14/NW/0034).
The trial opened on 1 May 2014. Follow-up was for a
minimum 24 months plus a 90 day window to attend the
screening invitation. Participants were recruited by trained
researchers at their screening appointment and all provided
written informed consent. For children aged 12–15 years,
proxy consent was by the parent/guardian with, where appro-
priate, assent from the child. Trial management is described in
ESM Methods, Trial management.
Participants were allocated 1:1 to annual screening (control
arm, current care) or individualised, risk-based, variable-
interval screening with recall at 6, 12 or 24 months for those
at high, medium and low risk, respectively. A purpose-built,
dynamic data warehouse linking primary and secondary care
demographic, retinopathy and systemic risk factor data popu-
lated the baseline and follow-up electronic case report forms
(OpenClinica, v3.12; OpenClinica, USA). Block
randomisation generated by an independent statistician was
conducted using a bespoke, validated electronic system at
the Clinical Trials Research Centre, with stratification by clin-
ic and age using random blocks of four and six for participants
aged ≥16 years, and blocks of two for those aged <16 years to
account for small numbers. Screening staff and clinical asses-
sors were observer-masked to the intervention arm, risk calcu-
lation and screening interval.
Procedures Each participant’s risk of becoming screen-
positive was assessed by a risk-calculation engine (RCE) that
was specifically developed for the RCT and is described in
detail elsewhere [19]. Briefly, the RCE uses data on retinop-
athy levels and demographic and clinical risk factors from the
local population and the individual to estimate the likelihood
of progression for that individual over a given time period.
An RCE development dataset comprised 5 years’ retinop-
athy, demographic and clinical data to 4 February 2014 held in
the ISDR data warehouse from 11,806 individuals with diabe-
tes. Participants and their general practitioners had agreed to
data sharing. The RCE is a Markov multi-state model, with
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states defined by retinopathy level (both eyes) and transitions
dependent on risk factors including historical retinopathy data.
Candidate risk factors were identified in collaboration with the
PPI group and selected as informative using the corrected
Akaike’s information criterion method. Risk factors in the
development dataset that were identified and included in the
model were age, time since diagnosis of diabetes, HbA1c,
systolic BP and total cholesterol. The time periods of 6, 12
and 24 months and a risk threshold of 2.5% were selected as
agreed with the PPI group. The RCE showed good discrimi-
natory ability. Corrected AUCs for 6, 12 and 24 months were
0.88 (95% CI 0.83, 0.93), 0.90 (95% CI 0.87, 0.93) and 0.91
(95% CI 0.87, 0.94), respectively. Sensitivities and specific-
ities for a 2.5% risk were, respectively, 0.61 and 0.93 for
6 months, 0.67 and 0.90 for 12 months, and 0.82 and 0.81
for 24 months. Using the 2.5% threshold, the corrected C-
index for the model was 0.687 [19].
At each screening visit during the trial, the RCE calculated
a participant’s risk of becoming screen-positive using auto-
matic exchanges of retinopathy data from the screening soft-
ware (OptoMize v4.3; EMIS Health, UK) and risk factor data
held in the data warehouse and randomisation databases. The
data warehouse was updated with clinical data from primary
care every 2 months. Participants were allocated to a high-,
medium- or low-risk group against the 2.5% threshold. The
screening interval could change at each follow-up visit.
Participants in the control arm continued with invitations to
annual screening, with risk recorded for future analysis.
Participants who were screen-positive attended for slit-
lamp biomicroscopy to determine the presence of STDR (true
positive). Participants with a false-positive result were
reconsented and re-entered the trial. Participants were free to
withdraw consent at any time without providing a reason.
Outcomes The primary outcome of attendance at first follow-
up visit (6, 12 or 24 months) assessed the safety of
individualised screening. Non-attendance was defined as fail-
ure to attend any appointment within 90 days of the follow-up
invitation, irrespective of the number of invitations.
Secondary outcomes measuring safety and efficacy report-
ed here include STDR, visual acuity (recorded as log of the
minimum angle of resolution), visual impairment (visual
acuity ≥+0.30 and ≥0.50), screen-positive results and rates
of retinopathy treatment over the 24 months (see ESM
Methods, Secondary outcomes). Quality-adjusted life-years
(QALYs) were used to produce cost-effectiveness estimates.
Statistical analysis Our primary hypothesis was that atten-
dance rates at first follow-up would be equivalent in the two
arms with a 5% equivalence margin. The estimated minimum
sample size was 4460 (90% power, 2.5% one-sided type 1
error, assuming the same attendance rate in both arms and
allowing for 6% per annum loss over 24 months). Further
details, including of a sample size review during the recruit-
ment phase, are in ESMMethods, Sample size. Our secondary
hypothesis was that STDR detection was non-inferior in the
individualised arm at a prespecified margin of 1.5%.
Primary equivalence and non-inferiority analyses followed
a per-protocol approach supported by secondary intention-to-
treat analyses [20]. Adherence to protocol for attendance was
considered at the first follow-up visit and by 24 months
(+90 days) for STDR. Multiple imputations generated using
generalised linear models (GLMs) dependent on baseline
characteristics (PROC multiple imputation; SAS v9.3; SAS
Institute, USA), assessed the effect of missing values on both
per-protocol and intention-to-treat datasets.
Within the three risk groups of the individualised arm,
equivalence in attendance rates between the two arms and
non-inferiority in detection of STDR were explored.
Participants in the control arm were allocated to risk groups
based on the RCE risks at baseline. GLMs were fitted with
arm, level of risk and their interaction added as factors.
Health economics The costs of routine screening were
measured using a mixed micro-costing and observational
health economics analysis over a 2 year time horizon (see
ESM Methods, Costs). Societal costs, including participant
and companion costs, collected using a bespoke question-
naire, comprised time lost from work (productivity losses)
and travel and parking costs. A detailed workplace analysis,
measuring resources and staff time to deliver the screening
programme, was conducted at each screening centre. This
ingredient-based, bottom-up approach enabled a current
resource-based cost to be attributed to the cost of screening
each individual, taking into account both attendees and the
related costs of non-attendance. We estimated the additional
costs of running the RCE using a screen population size of
22,000 (Liverpool). Treatment costs were excluded as the
2 year time horizon was felt to limit any inference that could
be attributed to lifetime cost (see ESM Methods, Costs).
A sample of the first participants enrolled into the RCT
(n = 868) completed the EuroQol Five-Dimension
Questionnaire (EQ-5D) five-level version (EQ-5D-5L) [21]
and the Health Utilities Index Mark 3 (HUI3) [22] question-
naire at baseline and follow-up visits. Health state utilities
were mapped [23] from the EQ-5D-5L to the EQ-5D three-
level version and used a UK population tariff [24].We applied
a relevant Canadian tariff [25] to health state classifications of
the HUI3 in the absence of an English or UK valuation set.
Discounting was not applied, as both costs and QALYs were
assumed to be assigned and incurred on an annual basis.
Further detail is available in ESM Methods, Utilities and
quality-adjusted life-years.
A detailed description of the cost-effectiveness analysis is
available in ESM Methods, Cost-effectiveness methodology.
A 90 day attendance window was utilised with a further
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90 days added at 24 months to allow for the compounding lag
in scheduling (see ESM Figs 1 and 2). We conducted multiple
imputation of chained equations using available case data and
followed guidance for best practice [26]. QALYs were
derived using AUC, and incremental effects were estimated
through ordinary least squares regression (for the univariate
distributions of complete cases) and seemingly unrelated
regressions (for the joint distributions of multiply imputed
sets) on baseline utilities. We present unadjusted estimates
as sensitivity analyses. We bootstrapped these regressions to
characterise sampling distributions and derive 95% bias-
corrected CIs around trial arm means and mean differences
[27]. Intention-to-treat analyses were conducted in Stata/SE
(Release 16; StataCorp, USA) from an NHS/societal perspec-
tive, and post-multiple imputation analyses followed Rubin’s
combination rules for estimation within multiply imputed sets
[28].
Results
Figure 1 summarises the trial profile showing the numbers for
eligibility, allocation and withdrawals, and per-protocol and
intention-to-treat datasets for the primary analysis. From 1
May 2014, 4538 participants were enrolled; four withdrew
after randomisation, requesting removal of their trial data.
Reasons for non-consent are shown in ESM Table 1.
Allocations were 2269 to the control arm and 2265 to the
individualised-interval arm (198, 211 and 1856 in the high-,
medium- and low-risk groups, respectively). Last follow-up
was on 5 September 2018.
The baseline characteristics of participants in the per-
protocol dataset are shown in Table 1 (similar distributions
for intention-to-treat are shown in ESM Table 2).
Participants were aged 14–100 years (median 63 years),
60.4% were male, 94.6% were white and 88.5% had type 2
diabetes. Compared with the other two risk groups, those in
the high-risk group were more likely to have type 1 diabetes,
had a longer diabetes duration and higher HbA1c, and were
less likely to have ever smoked. Proportions with any retinop-
athy by group within the individualised arm were 99.5%,
79.1% and 3.9% for those allocated to screening at 6, 12 and
24 months, respectively.
A total of 182 (4.0%) participants withdrew from the trial
before the first follow-up: 25 (0.6%) withdrew consent, 15
(0.3%) discontinued the intervention and 142 (3.2%) were lost
to follow-up (ESM Table 3). Withdrawals of consent were
higher in the individualised arm (0.9% vs 0.2%). Loss to
follow-up was higher in the individualised arm (101 [4.5%]
vs 41 [1.8%]), probably exacerbated by the longer follow-up
period of 24 months in the low-risk group (81.9% of the
individualised arm). A total of 15 participants prematurely
discontinued the intervention.
Attendance rates at first follow-up for the control and
individualised arms were 84.7% (1883/2224) and 83.6%
(1754/2097), respectively (difference in proportions −1.0
[95% CI −3.2, 1.2], per-protocol analysis). Against the
predefined acceptability margin (5%), the two arms were
regarded as equivalent (Fig. 2, Table 2). Protocol devia-
tions resulting in exclusion from this analysis occurred in
31 participants in the individualised arm; no safety effect
occurred (one participant was assigned to screening at 12
instead of 6 months and 30 were assigned to 6 or
12 months instead of 24 months). Similar results were
obtained from the intention-to-treat analysis. Per-protocol
and intention-to-treat analyses with multiple (Table 2)
and simple (ESM Table 4) imputation confirmed equiva-
lence in attendance rates between the two arms.
Figure 2 and Table 2 show the equivalence analysis within
the individualised arm. Equivalence in attendance rates at the
first follow-up visit was found for the low-risk group (control
85.7%, individualised 85.1%, difference −0.6% [95% CI
−2.9, 1.7]). For the medium-risk group, the difference in atten-
dance rates was also very small (control 81.7%, individualised
82.2%, difference 0.6% [95% CI −7.3, 8.4]); however, equiv-
alence was not confirmed due to the relatively wide CI.
Attendance rates were lower in the high-risk group (control
77.3%, individualised 72.3%, difference −5.0% [95% CI
−13.6, 3.5]) and equivalence was not observed. The atten-
dance rates observed over 12 months (≥1 attended appoint-
ment), however, were higher in the individualised arm
(89.1%) compared with the control arm (77.3%). A post hoc
analysis of attendance over 24 months gave similar results
(ESM Table 5).
The mean number of appointments per person by baseline
risk allocation over 24 months was 1.83, 1.06 and 0.85 in the
high-, medium- and low-risk groups, respectively. At least one
change in allocation from baseline was recorded as follows:
high-risk group, 48/160 (30.0%) participants were changed to
a longer screening interval; medium-risk group, 34/200
(17.0%) participants were changed to a shorter screening
interval and 84/200 (42.0%) were changed to a longer inter-
val; low-risk group, 142/1694 (8.4%) were participants
changed to a shorter interval (ESM Table 6). Overall, 132
participants were switched to a longer screening interval and
176 to a shorter interval.
There was no evidence of a loss of ability to detect STDR
over 24 months from baseline in the individualised arm (28/
1956; 1.4%) compared with the control arm (35/2042; 1.7%),
with a difference of −0.3 (95% CI −1.1, 0.5) (Table 2). Non-
inferiority was found within the low-risk group (control 0.6%,
individualised 0.2%, difference −0.3 [95% CI −0.9, 0.1]).
Non-inferiority was not confirmed for the high- and
medium-risk groups, probably because of small participant
numbers. Similar results were obtained with intention-to-
treat and multiple and simple imputation analyses.
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Four participants required treatment within 6 months of
being screen-positive: two for STDR (one in the control arm
and one in the high-risk group) and two for reasons other than
diabetic retinopathy.
Withdrawals, premature discontinuations and loss to
follow-up within 24 months showed a similar distribution
across the arms (ESM Table 7).
Further safety data are presented in ESM Results,
Secondary safety outcomes, and ESM Table 8. We did not
detect a clinically significant worsening of diabetes control or
an increase in visual impairment when comparing the groups.
As a secondary outcome, we investigated the efficacy of
individualised screening using data on numbers of attended
appointments and rates of screen-positive events across
Eligibility
Number eligible to be invited to participate in the RCT and who attended 
screening clinics staffed by ISDR researchers (n=8607)
Excluded (n=4069):
Consent not sought (n=293)
Consent not provided (n=3503)
Consented but not randomised (n=273)
Randomised (n=4538)
Withdrew and requested all trial data 
to be destroyed (n=4)
Individualised-interval arm (n=2265)Control arm (n=2269)
Allocation
Protocol deviations (n=0)
Per protocol  
(n=2269)
2224 analysed
45 unknown
outcome value: 
4 withdrew  
consent 
41 lost to
follow-up
Intention to treat  
(n=2269)
2224 analysed
45 unknown
outcome value: 
4 withdrew 
consent
41 lost to
follow-up
Allocated to 
6 months at 
baseline 
(n=198)
Allocated to 
12 months
at baseline 
(n=211)
Allocated to 
24 months
at baseline 
(n=1856)
Protocol deviations (n=31)
Per protocol  
(n=2234)
2097 analysed
137 unknown 
outcome value: 
21 withdrew 
consent 
101 lost to
follow-up
15 discontinued 
intervention
Intention to treat  
(n=2265)
2143 analysed
122 unknown 
outcome value: 
21 withdrew 
consent
101 lost to
follow-up
Primary analysis: attendance at first follow-up visit 
Fig. 1 CONSORT 2010 flow
diagram
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Table 1 Participant baseline characteristics by arm and screening interval allocation in 4503 participants in the per-protocol dataset
Baseline
characteristic
Arm Baseline risk groupa Overall total
Fixed (12 months) Individualised High Medium Low
nb 2269 2234 197 211 1826 4503
Sex, n (%)
Male 1358 (59.9) 1360 (60.9) 124 (62.9) 135 (64.0) 1101 (60.3) 2718 (60.4)
Female 911 (40.1) 874 (39.1) 73 (37.1) 76 (36.0) 725 (39.7) 1785 (39.6)
Ethnicity, n (%)
White 2140 (94.3) 2120 (94.9) 180 (91.4) 204 (96.7) 1736 (95.1) 4260 (94.6)
Asianc 48 (2.1) 30 (1.3) 2 (1.0) 3 (1.4) 25 (1.4) 78 (1.7)
Black 40 (1.8) 43 (1.9) 6 (3.0) 3 (1.4) 34 (1.9) 83 (1.8)
Chinese 7 (0.3) 6 (0.3) 1 (0.5) 1 (0.5) 4 (0.2) 13 (0.3)
Other 25 (1.1) 29 (1.3) 8 (4.1) 0 (0.0) 21 (1.2) 54 (1.2)
Unknown 9 (0.4) 6 (0.3) 0 (0.0) 0 (0.0) 6 (0.3) 15 (0.3)
Smoking status, n (%)
Smoker 419 (18.5) 364 (16.3) 26 (13.2) 39 (18.5) 299 (16.4) 783 (17.4)
Ex-smoker 877 (38.7) 899 (40.2) 69 (35.0) 76 (36.0) 754 (41.3) 1776 (39.4)
Non-smoker 965 (42.5) 967 (43.3) 102 (51.8) 96 (45.5) 769 (42.1) 1932 (42.9)
Unknown 8 (0.4) 4 (0.2) 0 (0.0) 0 (0.0) 4 (0.2) 12 (0.3)
Diabetes type, n (%)
Type 1 80 (3.5) 99 (4.4) 38 (19.3) 14 (6.6) 47 (2.6) 179 (4.0)
Type 2 2024 (89.2) 1962 (87.8) 140 (71.1) 180 (85.3) 1642 (89.9) 3986 (88.5)
Unknown 165 (7.3) 173 (7.7) 19 (9.6) 17 (8.1) 137 (7.5) 338 (7.5)
Age (years)
Observed, n 2269 2234 197 211 1826 4503
Median (IQR) 63.3 (55.0–71.0) 62.8 (54.8–70.3) 58.3 (49.9–66.2) 60.9 (53.4–69.8) 63.7 (55.9–70.8) 63.1 (54.9–70.7)
Range 14.1–100.7 15.4–91.3 17.5–86.8 15.4–86.8 16.8–91.3 14.1–100.7
Disease duration (years)
Observed, n 2267 2231 197 209 1825 4498
Unknown, n 2 3 0 2 1 5
Median (IQR) 6.9 (4.2–10.9) 7.0 (4.2–11.2) 11.1 (7.3–16.1) 9.8 (6.3–13.7) 6.4 (4.0–10.1) 7.0 (4.2–11.0)
Range 0.6–66.4 1.0–44.7 1.2–44.7 1.1–37.2 1.0–39.1 0.6–66.4
HbA1c
Observed, n 2269 2232 197 211 1824 4501
Unknown, n 0 2 0 0 2 2
mmol/mol
Median (IQR) 51 (44–61) 52 (44–63) 67 (53–84) 58 (51–67) 50 (44–60) 51 (44–62)
Range 26–146 28–155 33–134 34–155 28–104 26–155
%
Median (IQR) 6.8 (6.2–7.7) 6.9 (6.2–7.9) 8.3 (7.0–9.8) 7.5 (6.8–8.3) 6.7 (6.2–7.6) 6.8 (6.2–8.8)
Range 4.5–15.5 4.7–16.3 5.2–14.4 5.3–16.3 4.7–11.7 4.5–16.3
Systolic BP (mmHg)
Observed, n 2268 2234 197 211 1826 4502
Unknown, n 1 0 0 0 0 1
Median (IQR) 130.0
(121.0–138.0)
130.0
(122.0–138.0)
130.0
(124.0–138.0)
132.0
(124.0–140.0)
130.0
(122.0–138.0)
130.0
(122.0–138.0)
Range 84.0–213.0 90.0–204.0 93.0–175.0 95.0–204.0 90.0–200.0 84.0–213.0
Diastolic BP (mmHg)
Observed, n 2208 2180 193 201 1786 4388
Unknown, n 61 54 4 10 40 115
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24 months (ESM Table 9). Overall, 43.2% fewer screening
attendances were required in the individualised arm vs the
control arm (2008 vs 3536). Higher rates of screen-positive
events by screening episode attended were seen in the
individualised arm (individualised 5.1% [102/2008], control
4.5% [160/3536]). Within the individualised arm, the high-
risk group had the highest screen-positive rate (high 10.7%
[34/317], medium 6.0% [15/249], low 3.7% [53/1442]). In the
high-risk group, most of the screen-positive results were
because of eye disease other than diabetic retinopathy; the rate
of participants who were screen-positive for diabetic retinop-
athy was low, at 0.5% (7/1442). Screening episodes that
detected STDR were earlier in the individualised compared
with the control arm: 6–12 months 17.9% (5/28) vs 2.9%
(1/35); 12–18 months 32.1% (9/28) vs 60.0% (21/35).
A total of 868 participants completed the health economics
questionnaires. ESM Table 10 presents the summary costs
(2019/2020 values) associated with the screening programme.
The cost to the NHS was £28.73 per attendance and £12.73
per non-attendance, while additional productivity losses and
out-of-pocket payments by the patient accounted for £9.00.
Within-tr ial summary health economic and cost-
effectiveness data over the 2 year time horizon are reported
in Table 3, and additional data for the two arms in ESM
Tables 11 and 12. Multiple imputation supported the strict
dominance of individualised screening in terms of QALYs
gained and cost savings. Here, we briefly summarise the
results reporting conservative data from an analysis of
complete case QALYs and multiple imputation costs. Mean
incremental QALY scores did not show a statistically signif-
icant difference between the trial arms (EQ-5D 0.006 [95% CI
−0.039, 0.06], EuroQol Visual Analogue Score [EQ-VAS]
0.004 [95% CI −0.049, 0.052] and HUI3 −0.017 [95% CI
−0.083, 0.04]; Table 3), with agreement between societal pref-
erences (EQ-5D/HUI3) and individual preferences (EQ-
VAS). Incremental cost savings per participant with
individualised screening were: NHS perspective £17.34
(95% CI 17.02, 17.67); societal perspective £23.11 (95% CI
22.73, 23.53); corresponding to a reduction in total
programme costs of 20% (from £193,983 to £154,386) and
21% (from £248,114 to £195,348), respectively. The
individualised arm showed incremental savings across all
domains. The NHS perspective cost-effectiveness plane for
the EQ-5D andHUI3 shows the dominance of the intervention
arm in cost savings and expected maintenance of quality of
life (Fig. 3). While the intention had been to report cost-
effectiveness acceptability curves, the dominance in cost
reduction of risk-based screening and little fluctuation in
QALYs across all instruments rendered this metric uninfor-
mative, as the proportion cost-effective was inelastic to vary-
ing thresholds. See ESM Results, Health economics for
further details.
Table 1 (continued)
Baseline
characteristic
Arm Baseline risk groupa Overall total
Fixed (12 months) Individualised High Medium Low
Median (IQR) 76.0 (70.0–80.0) 76.0 (70.0–80.0) 77.0 (70.0–80.0) 77.0 (70.0–80.0) 76.0 (70.0–80.0) 76.0 (70.0–80.0)
Range 46.0–140.0 46.0–130.0 54.0–105.0 57.0–130.0 46.0–110.0 46.0–140.0
Total cholesterol (mmol/l)
Observed, n 2258 2224 196 209 1819 4482
Unknown, n 11 10 1 2 7 21
Median (IQR) 4.0 (3.4–4.7) 4.0 (3.4–4.7) 4.0 (3.4–4.9) 4.0 (3.4–4.6) 4.0 (3.5–4.7) 4.0 (3.4–4.7)
Range 1.4–8.1 1.8–9.7 2.0–9.0 2.2–7.6 1.8–9.7 1.4–9.7
Retinopathy level, n (%)d
R0 R0 1857 (81.8) 1800 (80.6) 1 (0.5) 44 (20.9) 1755 (96.1) 3657 (81.2)
R1 R0 262 (11.5) 296 (13.2) 58 (29.4) 167 (79.1) 71 (3.9) 558 (12.4)
R1 R1 146 (6.4) 137 (6.1) 137 (69.5) 0 (0.0) 0 (0.0) 283 (6.3)
a Differences across the three baseline risk groups (high, medium and low) were investigated, with statistically significant associations observed for
diabetes type (p < 0.0001; Cochran–Armitage test), retinopathy level (p < 0.0001; Fisher’s exact test) and age (p < 0.0001), disease duration (p < 0.0001),
HbA1c (p < 0.0001) and systolic BP (p = 0.0101) (all Jonckheere–Terpstra test). No statistically significant associations across the three baseline groups
were observed for sex (p = 0.30) or ethnicity (white vs non-white, p = 0.06) (Cochran–Armitage test), smoking status (p = 0.07; Fisher’s exact test), or
diastolic BP (p = 0.06) or total cholesterol (p = 0.80) (Jonckheere–Terpstra test)
b Participants randomised who did not withdraw or request all data to be destroyed
cAsian ethnicity group excludes individuals with Chinese ethnicity
d An additional five individuals with one eye were randomised into the trial (0.1%). Four had R0 (no diabetic retinopathy) in one eye and were
randomised into the fixed arm (0.2% of those in the fixed arm), while one had R1 (background retinopathy) in one eye and was randomised to the
individualised arm (<0.1% of those in the individualised arm) and allocated to 6 month follow-up (0.5% of those in the 6 months allocation)
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Fig. 2 Difference in the proportion of participants attending the first
follow-up visit between the two arms. ‘Overall’: primary analysis; ‘per
risk group’: high, medium and low risk groups within the individualised
arm. Point estimates and 95% confidence limits are provided. Vertical
dashed lines indicate 5% predefined equivalence margin. Diff, difference;
ITT, intention to treat; PP, per protocol
Table 3 Within-trial intention-to-
treat QALYs and costs per
participant: individualised vs
annual screening
Variable (n/N)a Mean difference (95% CI)b
Complete cases Multiple imputed
EQ-5D (539/868)
Unadjusted 0.012 (−0.097, 0.119) 0.043 (0.032, 0.055)
Baseline adjusted 0.006 (−0.039, 0.06) 0.044 (0.038, 0.05)
EQ-VAS (548/868)
Unadjusted −0.033 (−0.109, 0.044) 0.013 (0.005, 0.022)
Baseline adjusted 0.004 (−0.049, 0.052) 0.022 (0.017, 0.028)
HUI3 (408/868)
Unadjusted −0.016 (−0.135, 0.116) 0.068 (0.056, 0.081)
Baseline adjusted −0.017 (−0.083, 0.04) 0.051 (0.045, 0.058)
Costs (4389/4534) (£)
NHS perspective −17.44 (−18.57, −16.31) −17.34 (−17.67, −17.02)
Societal perspectivec −23.26 (−24.65, −21.92) −23.11 (−23.53, −22.73)
a n corresponds to the number of univariate complete cases out of the sampled set size of N
bWe estimated 95% CIs through 1000 iteration bootstrap regressions for univariate distributions of complete
cases, and seemingly unrelated regressions for multivariate distributions of multiple imputed sets
c Societal costs report the combination of NHS costs, participant or carer productivity losses, and out-of-pocket
expenses
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Discussion
Our study shows that individualised, risk-based, variable-
interval screening appears to be safe. Attendance at the first
follow-up visit was equivalent to that for annual screening and
secondary safety findings on the detection of STDR, visual
function and glycaemic control are supportive. Our approach
reduced the number of appointments by more than 40%.
There were no detectable effects on quality-of-life measures
and convincing cost savings.
Important strengths of our study are its RCT design, size,
independent oversight and direction from an expert PPI group.
We used the emerging technology of risk calculation, based
on integrating local clinical data in estimating risk, to intro-
duce a personalised approach. We implemented a mixed
Markov RCE into a clinical trial setting. Protocol deviations
were few (1.4% for primary outcome) and there were only
moderate numbers of withdrawals and loss to follow-up,
which are inevitable in a large RCT such as this. Findings
were similar in our per-protocol, intention-to-treat and multi-
ple imputation analyses, which followed current guidance on
equivalence studies [20].
Generalisation of our findings has some limitations.
Participants were enrolled from a single programme that has
been running for more than 30 years, and consequently had
relatively low rates of baseline diabetic retinopathy and
progression to STDR. Good glycaemic and BP control and a
relatively low proportion of participants with type 1 diabetes
(4.0%) might have biased the sample. Low rates of diabetic
retinopathy have been reported in other similar settings [29,
30], but our results should be treated with caution in areas with
a higher prevalence, poorer control of diabetes or wider ethnic
group representation, or in programmes during the set-up
process.
Our trial had only a 2 year time horizon, which is short in
the context of a life-long condition. With a move to extended-
interval screening in several countries, we wanted to provide
high-quality RCT evidence on how people act when given
risk-based, variable-interval screening. Previous studies have
derived risk models and used them in validation studies but
have not answered this question [31, 32]. To allow for two
cycles for the low-risk group would have extended the study
duration from 4 to 6 years. The low rates of retinopathy and
STDR in the low-risk group suggest that our findings on effec-
tiveness would be unlikely to change; most disease was
detected in the high- and medium-risk groups (STDR by
24 months: high-risk group 37 [12.2%], medium-risk group
12 [3.6%], low-risk group 14 [0.4%]). The cost savings with
variable-interval screening were substantial and are unlikely
to be lost over a longer time horizon, but to continue and
accrue year on year. Robust monitoring including fail-safe
mechanisms, such as in our design, should be included in
any future implementation of risk-based, variable-interval
screening.
A move to longer screening intervals for people at low risk
of diabetic retinopathy has previously been suggested
[33–35], but without convincing evidence on safety [10].
Overall, 19.0% of people invited to take part in our study
explicitly stated that they wished to remain on annual screen-
ing or did not want a change of interval (ESMTable 1). Health
professionals fear that extending screening intervals may
reduce perceptions of the importance of screening, leading
to loss of engagement and worse diabetes care. We did not
detect a worsening in glycaemic control. Our findings give
substantial reassurance that a 24 month interval for a low-
risk individuals with diabetes in a setting such as ours is safe.
However, for resource-poor or rural settings in low- and
middle-income countries, further research is required before
longer intervals can be contemplated.
Using a risk-based approach allows personalisation, offer-
ing better targeting of high-risk groups and improved patient
engagement. Around 15% of participants in this study had at
least one change in their risk-based interval; 59% (118/200) of
those allocated to attend annual screening (the current stan-
dard) experienced at least one change of interval (ESM
Table 6). Aspelund and colleagues have developed a similar
risk engine for diabetic retinopathy screening using modelling
coefficients from the 1990s [36] and conducted external vali-
dation in a Dutch cohort [31]. The strength of our RCE is that
it was populated with local data and can be regularly updated
with current data to reflect changing local progression rates.
For our approach to be more widely adopted, assessment in
other local and national screening programmes will be
−19
−18
−17
−16
−15
M
ea
n 
di
ffe
re
nc
e 
in
 s
cr
ee
ni
ng
 c
os
ts
 p
er
 p
at
ie
nt
 (
£)
−0.1 −0.05 0 0.05 0.1
Mean difference in QALYs per patient
HUI3 (complete case)
EQ-5D (complete case)
HUI3 (multiply imputed)
EQ-5D (multiply imputed)
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required. Some systems development from our research
setting to an implementation environment will be required.
Our parallel social science study demonstrated the acceptabil-
ity of variable-interval, risk-based screening to individuals
with diabetes and health professionals, provided that addition-
al monitoring and fail-safe mechanisms are included [37].
Further evaluation should include the effect of factors such
as the unexplained heterogeneity among screening
programmes in England in terms of grading outcomes and
screening uptake.
We targeted high-risk people using a 6 month screening
interval. Attendance rates in this group were lower in the
individualised arm (72.3%) compared with the control arm
(77.3%), but the shorter interval allowed more frequent screen-
ing and earlier detection of disease. There were higher relative
rates of STDR detection in the high- and medium-risk
individualised groups (13.4% and 3.9%) compared with 1.7%
in the control arm, with very low rates in the low-risk group
(0.2%). Our study was powered for equivalence with all risk
groups combined and not for the risk group comparisons.
Despite the hypothesis of equivalence not being supported in
the high-risk group, the attendance rates observed over a period
of 12 months were considerably higher in the individualised
arm compared with the control arm (89.1% vs 77.3%).
Including systemic clinical risk factors (HbA1c, systolic
BP, lipids) adds value in several ways. It allows the introduc-
tion of a high-risk group with earlier detection of STDR. It
also improves patient engagement by linking retinopathy to
systemic control; our PPI group strongly advised that includ-
ing clinical data reinforces the message that control is crucial
in managing complications. Including systemic risk factors
also improves the accuracy of identifying low-risk patients
when compared with simpler stratification strategies as
suggested for the UK [9], while maintaining a desirable level
of sensitivity. A post hoc analysis of our RCT dataset estimat-
ed that a simpler stratification approach [9] would allocate
66.9% of participants at baseline to a 24 month screening
interval (compared with 81.9% in ISDR) and 33.1% to
12 months (data not shown). We have observed that multivar-
iate risk models tend to require a lower frequency of eye
examinations, and consequently are likely to be more cost-
effective than current care [38].
Adding systemic risk factors may not be feasible in many
settings where it has proved difficult to reliably link primary
and secondary care data because of issues with data ownership
and IT systemmanagement. We overcame this through strong
support from local health commissioners and primary-care
research groups. We needed to develop bespoke data process-
ing, imputation and data validation processes. We included
this in our cost-effectiveness analysis.
Our data show convincing evidence that an individualised
approach provides considerable cost savings compared with
annual screening. In addition, moving to variable-interval,
risk-based screening did not compromise participants’ quality
of life. Incremental screening cost savings of £17.34 were
achieved (NHS perspective), rising to £23.11 (societal
perspective) per participant over the 2 years, a reduction in
total programme costs of 20% and 21%, respectively. A key
driver in achieving cost-effectiveness was the reduction in
unnecessary appointments and efficient use of administrative
time. In a screening population such as in Liverpool (22,909
invitations in 2018–2019), this may amount to annual savings
in the region of £199,000. In England (screening population
2.76 million [2018–2019] [39]), this could amount to around
£23.9 million in annual savings for the NHS, rising to £31.9
million from a societal perspective. Such resources could be
used to target groups that are hard to reach and those at high
risk of visual impairment, and to more cost-efficiently screen
the expanding population of individuals with diabetes.
Furthermore, those in low-risk groups would be spared the
inconvenience and additional personal cost of attending super-
fluous appointments.
The large number of observations and the accuracy of the
true resource cost of screening are strengths of our cost-
effectiveness analysis. The work could have been further
strengthened by taking a long-term time horizon as discussed
above and including the costs of treatment and blindness
averted. Collecting quality-of-life data from every participant
in the study would also have strengthened the analysis; our
sample size was chosen to minimise disruption in the screen-
ing clinic. While methods of multiple imputation involve
varied assumptions, the agreement between our complete case
and multiply imputed quality-of-life data, across instruments
and adjustments, is encouraging in viewing individualised
screening as a cost minimiser (see supporting discussion in
ESM Discussion).
Our data on efficacy show a higher efficiency of the
individualised approach, with a greater proportion of screen-
ing episodes being positive (5.1% vs 4.5% in the control arm).
A number of benefits include a lower burden of appointments,
earlier detection of STDR for people at high-risk and an
increased capacity to see individuals who have been newly
diagnosed with diabetes. Furthermore, in the era of
personalised care, a shortened screening interval in people at
high risk might increase the focus on risk factor control and
engagement with screening.
For people identified by our RCE as being at low risk, the
rates of screen-positive for diabetic retinopathy were very low
at 0.5% and even lower for STDR at under 0.2%. This is likely
to apply elsewhere, but should not be applied in territories
without an established systematic screening programme,
where the first-pass prevalence will be high. The design
of our study and the concerns around safety restricted
us to a maximum screening interval of 24 months.
However, our data suggest that extending intervals
beyond 2 years would be reasonable.
67Diabetologia  (2021) 64:56–69
In conclusion, our study, the largest RCT performed to date
in ophthalmology or screening, should reassure all stake-
holders in diabetes care that extended and personalised inter-
val screening can be safely and effectively introduced in
established systematic screening programmes. Our evidence
is over a 2 year time horizon, so for implementation the long
time frame of the disease should be addressed by continuous
monitoring of attendance, retinopathy rates and grading qual-
ity. It is also applicable to other settings where clinical data are
available, such as in healthcare-delivery organisations and
polyclinics. Where current recommendations are for annual
screening, we provide evidence to support a move to variable
intervals with substantial reductions in cost.
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